SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Shank RP, Gardocki JF, Vaught JL. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:45060.
  • 2
    Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as mono-therapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia 1997;38(suppl 1):S346.
  • 3
    Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate mono-therapy for partial onset seizures. Epilepsia 1997;38:294300.
  • 4
    Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:21724.
  • 5
    Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:7638.
  • 6
    Ben-Menachim E, Henriksen O, Dam M, Schmidt D. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:53943.
  • 7
    Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600-mg daily dosages. Neurology 1996;46:168490.
  • 8
    Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600, 800, and 1000-mg daily dosages. Neurology 1996;46:167883.
  • 9
    Meador KJ, Loring DE, Huh K, Calagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:3914.
  • 10
    Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22:6595.
  • 11
    Aldenkamp AP, Alpherts WCJ, Blennow G, et al. Withdrawal of antiepileptic medication: effects on cognitive function in children. The results of the multicentre ‘Holmfrid’ study. Neurology 1993;43:4151.
  • 12
    Riekkinen PJ, Kalviasinen R, Aikia M, Partanen J, Sakso M, Sive-nius J. Cognitive and electrophysiological effects of vigabatrin and carbamazepine. Epilepsia 1990;31:620.
  • 13
    Curran HV, Java R. Memory and psychomotor effects of oxcar-bazepine in healthy normal volunteers. Eur J Clin Pharmacol 1993;44:2933.
  • 14
    Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of la-motrigine as first line add-on in patients with localized related (partial) epilepsy. J Epilepsy 1997;10:11721.
  • 15
    Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose-ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62:3726.
  • 16
    Edwards KR, Kamin M, and the Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate. Neurology 1997;48(suppl 2):S39.
  • 17
    Sackellares JC, Kamin K, and Topiramate TPS-TR Study Group. Onset of anticonvulsant effect of topiramate, a new antiepileptic drug (AED). Neurology 1997;48(suppl 2):S37.
  • 18
    Cohen J. Statistical power analysis for the behavioral sciences. New York : Academic Press, 1977.
  • 19
    Aldenkamp AP, Timble MR. Cognitive side-effects of antiepileptic drugs: fact or fiction Epilepsia 1996;37:82.
  • 20
    Alpherts WCJ, Aldenkamp AP. Computerized neuropsychological assessment in children with epilepsy. Epilepsia 1990;31(suppl 4):S3540.
  • 21
    Moerland MC, Aldenkamp AP, Alpherts WCJ. Computerized psychological testing in epilepsy. In: MaarseFJ, MauseFY, MulderLYM, SjouwWPM, AhhermanAE, eds. Computers in psychology: methods, instrumentation and psychodiagnostics. Lisse , The Netherlands : Swets & Zeitlinger, 1988:15764.
  • 22
    Aldenkamp AP, Vermeulen J, Alpherts WCJ, et al. Validity of computerized testing: patient dysfunction and complaints versus measured changes. In: DodsonWE, KinsbourneM, eds. Assessment of cognitive function. New York : Demos, 1992:5168.
  • 23
    McNair DM, Lorr M, Droppleman LF. Manual: Profile of Mood States-Revised. San Diego , CA : Educational and Industrial Testing Service, 1992.
  • 24
    Aldenkamp AP, Baker G, Pieters MSM, et al. The Neurotoxicity Scale: the validity of a patient-based scale assessing neurotoxicity. Epilepsy Res 1995;20:22939.
  • 25
    Aldenkamp AP, Baker G. The Neurotoxicity Scale-II: results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Epilepsy Res 1997;27:16573.
  • 26
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topira-mate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:3217.
  • 27
    Meador KJ. Assessing cognitive effects of a new AED without the bias of practice effects. Epilepsia 1997;38(suppl 3):S60.
  • 28
    Sachdeo RC. Topiramate: clinical profile in epilepsy, Clin Pharmacokinet 1998;34:33546.